Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | ACACB | O00763 | 1/20 | 0.51 |
| ▸ | KIF11 | P52732 | 1/20 | 0.51 |
| ▸ | TPH1 | P17752 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 1/20 | 0.49 |
| ▸ | FAP | Q12884 | 1/20 | 0.49 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.49 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.49 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.49 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1309076 | 1.00 | LDHA (0.59) | LDHASLC6A4CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL7250996 | 1.00 | LDHA (0.59) | LDHASLC6A4CYP1A2CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL5934842 | 0.98 | LDHA (0.57) | LDHASLC6A4CYP1A2CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL7301098 | 0.98 | LDHA (0.57) | LDHASLC6A4CYP1A2CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL5934840 | 0.98 | LDHA (0.57) | LDHASLC6A4CYP1A2CYP2D6CYP2C19 | |
| Iodide SCHEMBL28191565 | 0.97 | LDHA (0.56) | LDHASLC6A4CYP1A2CYP2D6CYP2C19 | |
| Bromide SCHEMBL28190903 | 0.97 | LDHA (0.56) | LDHASLC6A4CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL539240 | 0.95 | LDHA (0.54) | LDHASLC6A4CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL539241 | 0.95 | LDHA (0.54) | LDHASLC6A4CYP1A2CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL540603 | 0.94 | TPH1 (0.54) | LDHASLC6A4CYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10669242-B2 | Clostridium difficile toxin inhibitors | Venenum Biodesign, LLC (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190194147-A1 | Novel Clostridium Difficile Toxin Inhibitors | Venenum Biodesign, LLC (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2017214359-A1 | NOVEL CLOSTRIDIUM DIFFICILE TOXIN INHIBITORS | VENENUM BIODESIGN LLC (US) | 2017-12-14 | — | — | WO | disclosed |
| US-20110274638-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREON IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-11-10 | — | — | US | disclosed |
| EP-2342194-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | Galderma Research & Development (FR) | 2011-07-13 | — | — | EP | disclosed |
| US-7291619-B2 | Melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-7186715-B2 | Piperazine- and piperidine-derivatives as melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-03-06 | — | — | US | disclosed |
| US-7157463-B2 | Substituted piperidines/piperazines as melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-7067525-B2 | Compounds useful as modulators of Melanocortin Receptors and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB CO. (US) | 2006-06-27 | — | — | US | disclosed |
| US-20060025403-A1 | Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same | YU GUIXUE | 2006-02-02 | — | — | US | disclosed |
| US-20030069169-A1 | Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-10 | — | — | US | disclosed |
| WO-2002059107-A1 | SUBSTITUTED PIPERIDINES/PIPERAZINES AS MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002059108-A1 | MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002059117-A1 | PIPERAZINE- AND PIPERIDINE-DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
| US-6410548-B2 | THERAPY FOR OBESITY, DIABETES, SEXUAL DISORDERS | MERCK & CO., INC. | 2002-06-25 | — | — | US | disclosed |
| US-20010029259-A1 | Spiropiperidine derivatives as melanocortin receptor agonists | MERCK SHARP & DOHME CORP. | 2001-10-11 | — | — | US | disclosed |
| EP-1085869-A4 | SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | MERCK & CO INC (US) | 2001-10-04 | — | — | EP | disclosed |
| US-6294534-B1 | TREATMENT OF DISORDERS RESPONSIVE TO THE ACTIVATION OF MELANOCORTIN RECEPTORS, SUCH AS OBESITY, DIABETES OR MALE OR FEMALE SEXUAL DYSFUNCTION. | MERCK & CO., INC. | 2001-09-25 | — | — | US | disclosed |
| EP-1085869-A1 | SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999064002-A1 | SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069169-A1 | Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders | MC4R, MC3R, MC1R | LDHA 4737/4885SLC6A4 638/4885CYP1A2 1847/4885 |
| US-20060025403-A1 | Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same | MC3R, MC2R, MC4R | LDHA 4665/4885SLC6A4 481/4885CYP1A2 363/4885 |
| US-20190194147-A1 | Novel Clostridium Difficile Toxin Inhibitors | GABRA5, GABRA1, GABRA4 | LDHA 3306/4885SLC6A4 532/4885CYP1A2 206/4885 |
| US-20010029259-A1 | Spiropiperidine derivatives as melanocortin receptor agonists | MC5R, MC4R, MC3R | LDHA 4616/4885SLC6A4 590/4885CYP1A2 1677/4885 |
| US-20110274638-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREON IN HUMAN MEDICINE AND IN COSMETICS | CYP2D6, CYP51A1, CYP2C19 | LDHA 1780/4885SLC6A4 3204/4885CYP1A2 25/4885 |
| US-10669242-B2 | Clostridium difficile toxin inhibitors | GABRA5, GABRA1, GABBR2 | LDHA 2715/4885SLC6A4 488/4885CYP1A2 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.